isobutyrylshikonin and Mouth-Neoplasms

isobutyrylshikonin has been researched along with Mouth-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for isobutyrylshikonin and Mouth-Neoplasms

ArticleYear
Isobutyrylshikonin has a potentially stronger cytotoxic effect in oral cancer cells than its analogue shikonin in vitro.
    Archives of oral biology, 2020, Volume: 116

    The aim of the present study was to identify the anticancer effects and the mechanisms of action of shikonin and its analogue isobutyrylshikonin in oral squamous carcinoma cells.. The cytotoxic effects of isobutyrylshikonin and shikonin in Ca9-22 and SCC-25 cells were analyzed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, flow cytometry analysis of Annexin V/Propidium Iodide (PI) staining, western blot analysis and immunohistochemistry.. Treatment with both isobutyrylshikonin and shikonin induced dose- and time-dependent apoptotic cell death in Ca9-22 cells, although the IC. The present study suggest that isobutyrylshikonin may be a more potent chemotherapeutic agent against oral cancer cells than shikonin. In addition, our data exhibit that both isobutyrylshikonin and shikonin induce caspase-dependent apoptosis via the mitochondrial pathway through accumulation of ROS in oral squamous carcinoma cells.

    Topics: Apoptosis; Cell Line, Tumor; Humans; Membrane Potential, Mitochondrial; Mouth Neoplasms; Naphthoquinones; Reactive Oxygen Species; Tumor Cells, Cultured

2020